Biotechnology

AB&B BIO-TECH-B

China Wisdom Bio-B Secures Clinical Trial Approval for mRNA RSV Vaccine

AB&B BIO-TECH-B FY2025 Annual Earnings Release on March 31, 2026 (BJT)

Zhonghui Bio's mRNA Monkeypox Vaccine Receives FDA IND Approval

ZHH Biology Expects Revenue Increase and Narrowed Net Loss for FY2025

China Wisdom Biologics-B initiates Phase III clinical trial for freeze-dried human rabies vaccine

Zhonghui Biopharma's Quadrivalent Influenza Vaccine Approved for All Age Groups

AB&B BIO-TECH-B released FY2024 Semi-Annual Earnings on August 28, 2025 (BJT), with actual revenue of HKD 7.53 M and EPS of HKD -0.467

AB&B BIO-TECH-B released FY2025 Semi-Annual Earnings on August 28, 2025 (BJT) with actual revenue of HKD 77.01 M and EPS of HKD -0.3654

AB&B BIO-TECH-B released FY2025 Q2 earnings on August 28, 2025 (BJT) with actual revenue of HKD 77.39 M and EPS of HKD -0.1039

AB&B BIO-TECH-B released FY2024 Q2 earnings on August 28, 2025 (BJT) with actual revenue of HKD 7.169 M and EPS of HKD -0.276

Zhonghui Biological-B Reports Strong Mid-Year Results

AB&B BIO-TECH-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Zhonghui Biotech's RSV Vaccine Receives Clinical Trial Approval in China and USA

AB&B BIO-TECH-B released FY2025 Q1 earnings on July 30 (BJT) with actual revenue of HKD 442.31 K and EPS of HKD -0.2597

AB&B BIO-TECH-B released FY2023 Annual Earnings on July 30, 2025 (BJT), with actual revenue of HKD 57.29 M and EPS of HKD -1.2956

AB&B BIO-TECH-B released FY2024 Q1 earnings on July 30 (BJT), actual revenue HKD 331.64 K, actual EPS HKD -0.1906

AB&B BIO-TECH-B released FY2024 earnings on July 30, 2025 (BJT) with actual revenue of HKD 281.02 M and EPS of HKD -0.7779

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02627

Ab&B Bio-Tech CO., LTD. has scheduled its first extraordinary general meeting for May 27, 2026, in Taizhou, allowing shareholders to participate both on-site and via eVoting. Key agenda items include abolishing the supervisory committee, amending governance policies, and appointing Ms. Lui Mei Ka as an independent non-executive director, along with Prism as the new auditors. The meeting emphasizes formal governance and transparent disclosure, adhering to Hong Kong listing rules. The company, listed in Hong Kong, operates in the biotech sector and aims to enhance investor engagement and compliance with governance standards.

Tip Ranks

Ab&B Bio-Tech Calls 2026 EGM to Overhaul Governance and Appoint New Auditor

513700

159892

Ab&B Bio-Tech CO., LTD. has nominated Ms. Lui Mei Ka as an independent non-executive director, pending shareholder approval. This appointment aims to enhance corporate governance following the departure of Mr. Cheng Qianwen. Ms. Lui brings extensive experience in financial management and compliance within Hong Kong-listed firms. Ab&B Bio-Tech, listed on the Hong Kong Stock Exchange, focuses on biopharmaceutical research and technologies in the life sciences sector, with a market cap of HK$11.54B.

Penghua CSI HK Connect Health Care Composite ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Ab&B Bio-Tech Strengthens Board With New Independent Director Nomination

588130

516500

Ab&B Bio-Tech CO., LTD. JS plans to abolish its Supervisory Committee and transfer oversight functions to the Board’s Audit Committee, aligning governance with operational needs and PRC company law. This change, subject to shareholder approval, will streamline internal oversight and amend the Articles of Association. Additionally, the company has reconstituted its Strategy Committee, appointing An Youcai as chairman, indicating a refreshed governance framework. Ab&B Bio-Tech operates in the biotechnology sector and is listed in Hong Kong, focusing on bio-tech products and services in the life sciences and healthcare supply chain.

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

China Southern Hang Seng Biotech ETF(QDII)

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

Ab&B Bio-Tech to Scrap Supervisory Committee and Revamp Governance Framework

06693

02630

03788

02575

01989

03330

09690

02598

02706

CHIFENG GOLD(06693) fell 25.1%, with a trading turnover 1.4 Billion HKD, and a year-to-date rose 5.9%. VIGONVITA-B(02630) fell 15.79%, with a trading turnover 8.4 Million HKD, and a year-to-date rose 29.6%. HANKING GOLD(03788) fell 13.57%, with a trading turnover 54.0 Million HKD, and a year-to-date fell 4.7%.

Top Gainers&Losers

CHIFENG GOLD

VIGONVITA-B

HANKING GOLD

XUANZHUBIO-B

DELTON

LINGBAO GOLD

TUHU-W

LIANLIAN

HAIZHI TECH GP

Top 10 HK Stock Losers (3.23)

AB&B BIO-TECH-B rose 18.65%; Rongchang Bio rose 6.96%, with a transaction volume of HKD 96.96 million; Sanofi Pharmaceutical rose 3.60%, with a transaction volume of HKD 88.01 million; BeiGene rose 1.50%, with a transaction volume of HKD 79.07 million; Innovent Biologics rose 1.31%, with a market value of HKD 147.7 billion

HK Stock Alerts

Hong Kong stock movement: AB&B BIO-TECH-B rises 18.65%, overseas vaccine cooperation agreement boosts market confidence

06869

02652

06127

01873

02546

00373

06166

03858

02670

AB&amp;B BIO-TECH-B(02627) fell 16.09%, with a trading turnover 43.7 Million HKD, and a year-to-date fell 4.1%. YOFC(06869) fell 12.39%, with a trading turnover 4.2 Billion HKD, and a year-to-date rose 170.8%. CF PHARMTECH(02652) fell 11.82%, with a trading turnover 63.2 Million HKD, and a year-to-date fell 29.7%.

YOFC

CF PHARMTECH

JOINN

VIVA BIOTECH

ZHIHUI MINING

ALLIED GROUP

JIAXIN INTL RES

YUNJI

Top 10 HK Stock Losers (3.17)

AB&B BIO-TECH-B fell 17.78%; CanSino Biologics rose 1.20%, with a transaction volume of HKD 710 million; Innovent Biologics fell 0.12%, with a transaction volume of HKD 698 million; 3SBio rose 4.01%, with a transaction volume of HKD 658 million; BeiGene fell 0.63%, with a market capitalization of HKD 267.7 billion

Hong Kong Stock Movement: AB&B BIO-TECH-B fell 17.78%, vaccine cooperation agreement raises profit concerns, market competition intensifies!

AB&B BIO-TECH-B fell 14.09%; CanSino Biologics rose 1.97%, with a transaction volume of HKD 641 million; Innovent Biologics rose 1.25%, with a transaction volume of HKD 594 million; 3SBio rose 4.92%, with a transaction volume of HKD 586 million; BeiGene rose 0.17%, with a market value of HKD 270.1 billion

Hong Kong Stock Movement: AB&B BIO-TECH-B fell 14.09%, overseas vaccine agreements raised profit concerns, market sentiment changed abruptly

00881

03881

00975

02386

01114

02661

00167

02889

01384

AB&amp;B BIO-TECH-B(02627) fell 19.72%, with a trading turnover 104.6 Million HKD, and a year-to-date rose 14.3%. ZHONGSHENG HLDG(00881) fell 15.42%, with a trading turnover 376.7 Million HKD, and a year-to-date fell 29.2%. CIDI(03881) fell 11.65%, with a trading turnover 4.5 Million HKD, and a year-to-date fell 90.5%.

ZHONGSHENG HLDG

CIDI

MONGOL MINING

SINOPEC SEG

Brilliance China

QINGSONG HEALTH

IDT INT'L

PATEO

DEEPEXI TECH

Top 10 HK Stock Losers (3.16)

AB&B BIO-TECH-B fell 18.22%; CanSino Biologics rose 5.26%, with a transaction volume of HKD 848 million; Innovent Biologics rose 3.77%, with a transaction volume of HKD 614 million; BeiGene rose 2.05%, with a transaction volume of HKD 310 million; Kelun-Biotech rose 4.81%, with a market value of HKD 96.5 billion

Hong Kong Stock Movement: AB&B BIO-TECH-B signs a strategic cooperation agreement but falls 18.22%, market doubts the effectiveness of the cooperation

AB&B BIO-TECH-B(02627.HK)